Answers are grounded in this paper and cite their sources.
Clinical review highlights severe toxicity profiles in renal cancer and melanoma patients, suggesting mechanistic insights could improve treatment safety.
Immunotherapy with IL-2 represents a major breakthrough in the management of renal cell carcinoma and malignant melanoma. At present, the toxicity of most IL-2 regimens is severe and prohibitive for clinicians not intimately familiar with the myriad of side effects associated with its use. The elucidation of the mechanism by which the lymphokine induces tumor regression, the vascular leak syndrome and other side effects will permit IL-2 to be used more safely and effectively.
No takes yet. Share an insight, caveat, or question.
Mier et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: